PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of annrheumdAnnals of the Rheumatic DiseasesVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
Ann Rheum Dis. 1981 August; 40(4): 355–359.
PMCID: PMC1000728

Azathioprine in rheumatoid arthritis: double-blind study of full versus half doses versus placebo.

Abstract

To test whether azathioprine in effective in rheumatoid arthritis in doses smaller than those normally used the drug was tested at 2 dosage levels, 2.5 and 1.25 mg/kg/day (2.5 AZ and 1.25 AZ), against placebo under double-blind conditions over 24 weeks. Dropouts were 7 out of 15 in the 2.5 AZ group, 4 out of 14 in the 1.25 AZ group, and 2 out of 13 in the placebo group. Some significant improvement occurred in all 3 groups, including those on placebo. However, the 2.5 AZ group fared significantly better than the placebo group, while the 1.25 AZ group results tended to fall between the other 2 groups. We conclude that, in order to obtain the reported effectiveness of azathioprine in rheumatoid arthritis, it is necessary to start treatment with 2.5 mg/kg/day. Halving this dosage reduces the effectiveness of the drug.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (646K), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Kinlen LJ, Sheil AG, Peto J, Doll R. Collaborative United Kingdom-Australasian study of cancer in patients treated with immunosuppressive drugs. Br Med J. 1979 Dec 8;2(6203):1461–1466. [PMC free article] [PubMed]
  • Mason M, Currey HL, Barnes CG, Dunne JF, Hazleman BL, Strickland ID. Azathioprine in rheumatoid arthritis. Br Med J. 1969 Feb 15;1(5641):420–422. [PMC free article] [PubMed]
  • GOEBEL KM, Janzen R, Joseph K, Börngen U. Disparity between clinical and immune responses in a controlled trial of azathioprine in rheumatoid arthritis. Eur J Clin Pharmacol. 1976 Mar 22;09(5-6):405–410. [PubMed]
  • Pinals RS. Azathioprine in the treatment of chronic polyarthritis: longterm results and adverse effects in 25 patients. J Rheumatol. 1976 Jun;3(2):140–144. [PubMed]
  • Cade R, Stein G, Pickering M, Schlein E, Spooner G. Low dose, long-term treatment of rheumatoid arthritis with azathioprine. South Med J. 1976 Apr;69(4):388–392. [PubMed]
  • Dwosh IL, Stein HB, Urowitz MB, Smythe HA, Hunter T, Ogryzlo MA. Azathioprine in early rheumatoid arthritis. Comparison with gold and chloroquine. Arthritis Rheum. 1977 Mar;20(2):685–692. [PubMed]
  • Taves DR. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther. 1974 May;15(5):443–453. [PubMed]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Group